Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vaccinex, Inc. (VCNX)
USD1.16
-0.13 (-10.08%)
US OTC Healthcare Biotechnology
Address
1895 Mount Hope Avenue 14620
Rochester, NY, US
Rochester, NY, US
CEO
Maurice Zauderer
Website
vaccinex.com
IPO
2018-08-09
CIK 1205922 ISIN US9186403013
Description
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.16
-0.13 (-10.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2.5K
Beta
0.65
Float Shares
1.18M
Free Float %
44.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +28.21% | -2.91% | +42.88% | -7.41% | +38.89% | -98.84% | -99.80% | -99.96% | -99.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
1.16
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-217.65
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+5.4% ★ Q4'24: +155.2% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+79.7% ★ Q4'24: +80.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,738.6% Q4'24: -1,846.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-3,100.2% Q4'24: -1,583.1% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'24: +377.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+352.7% Q4'24: +434.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'24: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
724.0K
est: 616.7K (+17.4%)
|
523.0K
est: 566.0K (-7.6%)
|
50.0K
est: 600.0K (-91.7%)
|
900.0K
est: 900.0K (+0.0%)
|
100.0K
est: 50.00M (-99.8%)
|
570.0K
est: 53.10M (-98.9%)
|
601.0K
est: 110.00M (-99.5%)
|
142.70M
est.
|
| EBITDA |
-28.90M
est: -616.7K (-4,587.0%)
|
-31.61M
est: -566.0K (-5,485.5%)
|
-28.06M
est: -600.0K (-4,575.8%)
|
-21.40M
est: -900.0K (-2,278.0%)
|
-19.61M
est: -50.00M (+60.8%)
|
-19.75M
est: -53.10M (+62.8%)
|
-18.54M
est: -110.00M (+83.1%)
|
-142.70M
est.
|
| EBIT |
-29.13M
est: -616.7K (-4,623.1%)
|
-31.86M
est: -566.0K (-5,529.5%)
|
-28.36M
est: -600.0K (-4,627.0%)
|
-21.57M
est: -900.0K (-2,296.8%)
|
-19.81M
est: -50.00M (+60.4%)
|
-19.87M
est: -53.10M (+62.6%)
|
-18.63M
est: -110.00M (+83.1%)
|
-142.70M
est.
|
| Net Income |
-29.52M
est: -1.60B (+98.2%)
|
-32.02M
est: -1.17B (+97.3%)
|
-28.85M
est: -687.62M (+95.8%)
|
-22.38M
est: -502.49M (+95.5%)
|
-19.72M
est: -61.71M (+68.0%)
|
-20.25M
est: -176.31M (+88.5%)
|
-18.63M
est: 290.91M (-106.4%)
|
542.16M
est.
|
| SGA |
4.62M
est: 29.65M (-84.4%)
|
6.67M
est: 27.21M (-75.5%)
|
7.41M
est: 28.85M (-74.3%)
|
6.23M
est: 43.27M (-85.6%)
|
6.20M
est: 2.40B (-99.7%)
|
6.88M
est: 2.55B (-99.7%)
|
6.79M
est: 5.29B (-99.9%)
|
6.86B
est.
|
| EPS |
-1,186.70
est: -761.25 (-55.9%)
|
-521.95
est: -557.55 (+6.4%)
|
-322.50
est: -327.60 (+1.6%)
|
-163.80
est: -239.40 (+31.6%)
|
-97.59
est: -29.40 (-231.9%)
|
-43.68
est: -84.00 (+48.0%)
|
-8.88
est: 138.60 (-106.4%)
|
258.30
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-15.88M
OE per share TTM
-9.31
Owner's Yield
-756.39%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
83.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
17.00
Insider transactions (90d)
0
Beneficial owners (>5%)
19
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALBERT D. FRIEDBERG | 8.44M | 62.00% | — | 8.44M | — | 10.00 | IN | or Place of Organization | 2018-08-24 | ↗ |
| 2 | FCMI PARENT CO. | 7.42M | 54.50% | — | 7.42M | — | 10.00 | CO | or Place of Organization | 2018-08-24 | ↗ |
| 3 | Point72 Asset Management, L.P. | 5.79M | 9.90% | — | 5.79M | — | — | PN | Delaware | 2024-02-09 | ↗ |
| 4 | Point72 Capital Advisors, Inc. | 5.79M | 9.90% | — | 5.79M | — | — | CO | Delaware | 2024-02-09 | ↗ |
| 5 | Steven A. Cohen | 5.79M | 9.90% | — | 5.79M | — | — | IN | United States | 2024-02-09 | ↗ |
| 6 | The Aberdeen Foundation | 1.90M | 9.40% | 1.90M | — | 1.90M | — | HC | United Kingdom | 2020-10-19 | ↗ |
| 7 | 27-4413262 | 1.23M | 9.90% | 990.2K | — | 1.23M | — | OO | Maryland | 2023-10-11 | ↗ |
| 8 | Identification Nos. of above persons (. | 1.23M | 9.90% | 990.2K | — | 1.23M | — | IN | States | 2023-10-11 | ↗ |
| 9 | FCMI FINANCIAL CORPORATION | 1.01M | 7.40% | — | 1.01M | — | 10.00 | CO | or Place of Organization | 2018-08-24 | ↗ |
| 10 | FRIEDBERG GLOBAL-MACRO HEDGE FUND LTD. | 583.3K | 4.30% | — | 583.3K | — | 10.00 | CO | or Place of Organization | 2018-08-24 | ↗ |
| 11 | FRIEDBERG MERCANTILE GROUP LTD. | 583.3K | 4.30% | — | 583.3K | — | 10.00 | CO | or Place of Organization | 2018-08-24 | ↗ |
| 12 | Maurice Zauderer | 426.2K | 15.40% | 1.9K | 424.3K | 1.9K | 424.3K | IN | — | 2024-09-20 | ↗ |
| 13 | Vaccinex (Rochester), L.L.C. | 422.3K | 15.20% | — | 422.3K | — | 422.3K | OO | — | 2024-09-20 | ↗ |
| 14 | Armistice Capital, LLC | 164.0K | 9.49% | — | 164.0K | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 15 | Steven Boyd | 164.0K | 9.49% | — | 164.0K | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 16 | PAN ATLANTIC BANK AND TRUST LIMITED | 37.6K | 0.30% | — | 37.6K | — | 10.00 | CO | or Place of Organization | 2018-08-24 | ↗ |
| 17 | PAN ATLANTIC HOLDINGS LTD. | 180.00 | 0.00% | — | 180.00 | — | 180.00 | CO | — | 2024-09-20 | ↗ |
| 18 | MSD Credit Opportunity Master Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2021-02-12 | ↗ |
| 19 | MSD Partners, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2021-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
1
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | — -27.0 (-100.0%) | — -92.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
5.00
Bullish
Ratio by volume
3.00
Bullish
Buys
15
Sells
3
Shares acquired
1.40M
Shares disposed
275.7K
Cash buys
7.00
Cash sales
—
Net activity
+1,119,829
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-14 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Common Stock | 46,153 | 3.25 | 150.0K | 297,941 | I | ↗ |
| 2024-11-14 | FRIEDBERG ALBERT | Director / 10% Owner | A-Award | A | Common Stock | 30,756 | 3.25 | 100.0K | 1,051,389 | I | ↗ |
| 2024-09-18 | Zauderer Maurice | Director / Officer / 10% Owner | M-Exempt | D | Warrant (Right to Buy) | 35,715 | 5.64 | 201.3K | 0 | I | ↗ |
| 2024-09-18 | FRIEDBERG ALBERT | Director / 10% Owner | M-Exempt | D | Warrant (Right to Buy) | 25,723 | 0.00 | 25.72 | 92,504 | I | ↗ |
| 2024-08-09 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 100 | 4.51 | 451.00 | 780,624 | — | ↗ |
| 2024-08-06 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 2,753 | 4.92 | 13.5K | 780,524 | — | ↗ |
| 2024-08-05 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 3,653 | 4.60 | 16.8K | 777,771 | — | ↗ |
| 2024-08-01 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 11,703 | 4.72 | 55.2K | 774,118 | — | ↗ |
| 2024-07-31 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 83,243 | 6.41 | 533.6K | 746,287 | — | ↗ |
| 2024-05-30 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 861 | 5.20 | 4.5K | 562,415 | — | ↗ |
| 2024-05-29 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 957 | 4.95 | 4.7K | 561,554 | — | ↗ |
| 2024-05-10 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 10,108 | 5.75 | 58.1K | 10,108 | — | ↗ |
| 2024-05-10 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 10,108 | 5.75 | 58.1K | 10,108 | — | ↗ |
| 2024-05-10 | Stecyk Chrystyna Bedrij | Director | A-Award | A | Stock Option (Right to Buy) | 10,108 | 5.75 | 58.1K | 10,108 | — | ↗ |
| 2024-05-10 | MANIAN BALA S | Director | A-Award | A | Stock Option (Right to Buy) | 2,685 | 5.75 | 15.4K | 2,685 | — | ↗ |
| 2024-05-10 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 10,108 | 5.75 | 58.1K | 10,108 | — | ↗ |
| 2024-04-19 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 282 | 4.73 | 1.3K | 560,597 | — | ↗ |
| 2024-03-28 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Common Stock | 38,610 | 7.77 | 300.0K | 138,138 | — | ↗ |
| 2024-03-28 | FRIEDBERG ALBERT | Director / 10% Owner | A-Award | A | Warrant (Right to Buy) | 102,960 | 7.64 | 786.6K | 102,960 | — | ↗ |
| 2024-03-21 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 1,877 | 8.21 | 15.4K | 1,877 | — | ↗ |
| 2024-03-21 | Smith Ernest S. | Officer | A-Award | A | Stock Option (Right to Buy) | 1,341 | 8.21 | 11.0K | 1,341 | — | ↗ |
| 2024-03-21 | Sanchez Jill | Officer | A-Award | A | Stock Option (Right to Buy) | 805 | 8.21 | 6.6K | 805 | — | ↗ |
| 2024-03-21 | Evans Elizabeth E. | Officer | A-Award | A | Stock Option (Right to Buy) | 1,341 | 8.21 | 11.0K | 1,341 | — | ↗ |
| 2024-03-20 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 1,877 | 9.15 | 17.2K | 1,877 | — | ↗ |
| 2024-03-20 | Smith Ernest S. | Officer | A-Award | A | Stock Option (Right to Buy) | 1,341 | 8.32 | 11.2K | 1,341 | — | ↗ |
| 2024-03-20 | Sanchez Jill | Officer | A-Award | A | Stock Option (Right to Buy) | 805 | 8.32 | 6.7K | 805 | — | ↗ |
| 2024-03-20 | Evans Elizabeth E. | Officer | A-Award | A | Stock Option (Right to Buy) | 1,341 | 8.32 | 11.2K | 1,341 | — | ↗ |
| 2024-03-14 | Sanchez Jill | Officer | — | D | Stock Option (Right to Buy) | 9 | 1,045.80 | 9.4K | 0 | — | ↗ |
| 2024-02-08 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Common Stock | 413,793 | 0.73 | 300.0K | 1,393,392 | — | ↗ |
| 2024-02-08 | FRIEDBERG ALBERT | Director / 10% Owner | A-Award | A | Common Stock | 1,655,172 | 0.73 | 1.20M | 6,402,966 | — | ↗ |
| 2023-12-26 | Van Strydonck, Gerald E. | Director | S-Sale | D | Common Stock | 3,149 | 0.72 | 2.3K | 0 | — | ↗ |
| 2023-12-08 | Van Strydonck, Gerald E. | Director | S-Sale | D | Common Stock | 1,334 | 0.67 | 893.78 | 3,149 | — | ↗ |
| 2023-11-02 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Warrant (Right to Buy) | 136,752 | 2.34 | 320.0K | 136,752 | — | ↗ |
| 2023-10-23 | Frieberg Jacob B. | Director | D-Return | D | Stock Option (Right to Buy) | 11,291 | 1.13 | 12.8K | 0 | — | ↗ |
| 2023-10-04 | Zauderer Maurice | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 0.97 | 4.9K | 22,116 | — | ↗ |
| 2023-10-03 | Zauderer Maurice | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 0.93 | 4.7K | 17,116 | — | ↗ |
| 2023-10-03 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Warrant (Right to Buy) | 3,000,000 | 1.00 | 3.00M | 3,000,000 | — | ↗ |
| 2023-09-29 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 11,291 | 1.13 | 12.8K | 11,291 | — | ↗ |
| 2023-09-22 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,051,282 | 0.16 | 320.0K | 7,193,973 | — | ↗ |
| 2023-06-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 2,414 | 5.34 | 12.9K | 2,414 | — | ↗ |
| 2023-05-15 | FRIEDBERG ALBERT | Director / 10% Owner | A-Award | A | Common Stock | 6,711,552 | 0.37 | 2.51M | 26,216,904 | — | ↗ |
| 2023-05-11 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 143,848 | 0.41 | 59.0K | 143,848 | — | ↗ |
| 2023-05-11 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 143,848 | 0.41 | 59.0K | 143,848 | — | ↗ |
| 2023-05-11 | Stecyk Chrystyna Bedrij | Director | A-Award | A | Stock Option (Right to Buy) | 143,848 | 0.41 | 59.0K | 143,848 | — | ↗ |
| 2023-05-11 | MANIAN BALA S | Director | A-Award | A | Stock Option (Right to Buy) | 143,848 | 0.41 | 59.0K | 143,848 | — | ↗ |
| 2023-05-11 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 143,848 | 0.41 | 59.0K | 143,848 | — | ↗ |
| 2023-03-31 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 56,000 | 0.44 | 24.6K | 56,000 | — | ↗ |
| 2023-03-31 | Smith Ernest S. | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.40 | 16.0K | 40,000 | — | ↗ |
| 2023-03-31 | Royer Scott E. | Officer | A-Award | A | Stock Option (Right to Buy) | 32,000 | 0.40 | 12.8K | 32,000 | — | ↗ |
| 2023-03-31 | Leonard John E. | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.40 | 8.0K | 20,000 | — | ↗ |
| 2023-03-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 32,107 | 0.40 | 12.8K | 32,107 | — | ↗ |
| 2023-03-31 | FRIEDBERG ALBERT | Director / 10% Owner | A-Award | A | Common Stock | 4,146,341 | 0.41 | 1.70M | 19,505,352 | — | ↗ |
| 2023-03-31 | Evans Elizabeth E. | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 0.40 | 16.0K | 40,000 | — | ↗ |
| 2022-12-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 19,852 | 0.65 | 12.8K | 19,852 | — | ↗ |
| 2022-12-06 | Zauderer Maurice | Officer | W-Will | A | Common Stock | 3,988 | 0.00 | — | 181,736 | — | ↗ |
| 2022-11-23 | Zauderer Maurice | Officer | A-Award | A | Common Stock | 1,511,430 | 0.53 | 800.0K | 4,410,984 | — | ↗ |
| 2022-11-23 | Van Strydonck, Gerald E. | Director | A-Award | A | Common Stock | 47,232 | 0.53 | 25.0K | 67,232 | — | ↗ |
| 2022-11-23 | Frieberg Jacob B. | Director | A-Award | A | Common Stock | 188,928 | 0.53 | 100.0K | 193,049 | — | ↗ |
| 2022-11-23 | FRIEDBERG ALBERT | Director | A-Award | A | Common Stock | 3,778,575 | 0.53 | 2.00M | 15,359,011 | — | ↗ |
| 2022-09-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 26,260 | 0.50 | 13.0K | 26,260 | — | ↗ |
| 2022-06-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 12,064 | 1.08 | 13.0K | 12,064 | — | ↗ |
| 2022-05-12 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 53,254 | 0.00 | — | 53,254 | — | ↗ |
| 2022-05-12 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 53,254 | 0.00 | — | 53,254 | — | ↗ |
| 2022-05-12 | Stecyk Chrystyna Bedrij | Director | A-Award | A | Stock Option (Right to Buy) | 53,254 | 1.12 | 59.6K | 53,254 | — | ↗ |
| 2022-05-12 | MANIAN BALA S | Director | A-Award | A | Stock Option (Right to Buy) | 53,254 | 0.00 | — | 53,254 | — | ↗ |
| 2022-05-12 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 53,254 | 1.12 | 59.6K | 53,254 | — | ↗ |
| 2022-04-01 | Zauderer Maurice | Officer | A-Award | A | Stock Option (Right to Buy) | 28,000 | 0.00 | — | 28,000 | — | ↗ |
| 2022-04-01 | Smith Ernest S. | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.29 | 25.8K | 20,000 | — | ↗ |
| 2022-04-01 | Royer Scott E. | Officer | A-Award | A | Stock Option (Right to Buy) | 16,000 | 0.00 | — | 16,000 | — | ↗ |
| 2022-04-01 | Leonard John E. | Officer | A-Award | A | Stock Option (Right to Buy) | 16,000 | 1.29 | 20.6K | 16,000 | — | ↗ |
| 2022-04-01 | Evans Elizabeth E. | Officer | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-03-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 10,032 | 1.32 | 13.2K | 10,032 | — | ↗ |
| 2022-02-23 | Van Strydonck, Gerald E. | Director | P-Purchase | A | Common Stock | 2,000 | 1.30 | 2.6K | 2,000 | — | ↗ |
| 2022-01-27 | Zauderer Maurice | Director / Officer | P-Purchase | A | Common Stock | 1,801,801 | 1.11 | 2.00M | 2,899,554 | — | ↗ |
| 2022-01-27 | Frieberg Jacob B. | Director | P-Purchase | A | Common Stock | 90,090 | 1.11 | 100.0K | 94,510 | — | ↗ |
| 2022-01-27 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 1,801,801 | 1.11 | 2.00M | 11,580,436 | — | ↗ |
| 2021-12-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 12,856 | 1.04 | 13.4K | 12,856 | — | ↗ |
| 2021-09-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 6,233 | 2.16 | 13.5K | 6,233 | — | ↗ |
| 2021-06-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 4,804 | 2.80 | 13.5K | 4,804 | — | ↗ |
| 2021-06-25 | Frieberg Jacob B. | Director | C-Conversion | A | Common Stock | 4,121 | 0.00 | — | 4,121 | — | ↗ |
| 2021-05-24 | FRIEDBERG ALBERT | Director / 10% Owner | C-Conversion | A | Common Stock | 1,180,051 | 0.00 | — | 8,810,652 | — | ↗ |
| 2021-05-11 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 28,586 | 2.15 | 61.5K | 28,586 | — | ↗ |
| 2021-05-11 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 28,586 | 2.15 | 61.5K | 28,586 | — | ↗ |
| 2021-05-11 | Stecyk Chrystyna Bedrij | Director | A-Award | A | Stock Option (Right to Buy) | 28,586 | 2.15 | 61.5K | 28,586 | — | ↗ |
| 2021-05-11 | MANIAN BALA S | Director | A-Award | A | Stock Option (Right to Buy) | 28,586 | 2.15 | 61.5K | 28,586 | — | ↗ |
| 2021-05-11 | Goater Jeff | Director | A-Award | A | Stock Option (Right to Buy) | 28,586 | 2.15 | 61.5K | 28,586 | — | ↗ |
| 2021-05-11 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 28,586 | 2.15 | 61.5K | 28,586 | — | ↗ |
| 2021-05-11 | Evans Elizabeth E. | Officer | — | D | Common Stock | 0 | 0.00 | — | 9,600 | — | ↗ |
| 2021-04-02 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 14,000 | 2.93 | 41.0K | 14,000 | — | ↗ |
| 2021-04-02 | Smith Ernest S. | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.93 | 29.3K | 10,000 | — | ↗ |
| 2021-04-02 | Royer Scott E. | Officer | A-Award | A | Stock Option (Right to Buy) | 6,000 | 2.93 | 17.6K | 6,000 | — | ↗ |
| 2021-04-02 | Leonard John E. | Officer | A-Award | A | Stock Option (Right to Buy) | 8,000 | 2.93 | 23.4K | 8,000 | — | ↗ |
| 2021-03-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 4,535 | 2.98 | 13.5K | 4,535 | — | ↗ |
| 2020-12-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 6,545 | 2.07 | 13.5K | 6,545 | — | ↗ |
| 2020-09-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 7,626 | 1.78 | 13.6K | 7,626 | — | ↗ |
| 2020-09-03 | Royer Scott E. | Officer | M-Exempt | A | Common Stock | 500 | 3.90 | 2.0K | 4,499 | — | ↗ |
| 2020-09-01 | Scala Robert | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 5.67 | 283.5K | 50,000 | — | ↗ |
| 2020-07-27 | Leonard John E. | Officer | M-Exempt | A | Common Stock | 1,000 | 3.90 | 3.9K | 1,000 | — | ↗ |
| 2020-07-24 | Leonard John E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,258 | 7.10 | 8.9K | 23,150 | D | ↗ |
| 2020-07-14 | Leonard John E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,000 | 3.90 | 3.9K | 3,000 | — | ↗ |
| 2020-07-10 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 1,126,760 | 3.55 | 4.00M | 1,710,093 | — | ↗ |
| 2020-06-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 3,756 | 3.61 | 13.6K | 3,756 | — | ↗ |
| 2020-05-14 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 15,679 | 3.95 | 61.9K | 15,679 | — | ↗ |
| 2020-05-14 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 15,679 | 3.95 | 61.9K | 15,679 | — | ↗ |
| 2020-05-14 | Stecyk Chrystyna Bedrij | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-14 | MANIAN BALA S | Director | A-Award | A | Stock Option (Right to Buy) | 15,679 | 3.95 | 61.9K | 15,679 | — | ↗ |
| 2020-05-14 | Goater Jeff | Director | A-Award | A | Stock Option (Right to Buy) | 15,679 | 3.95 | 61.9K | 15,679 | — | ↗ |
| 2020-05-14 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 15,679 | 3.95 | 61.9K | 15,679 | — | ↗ |
| 2020-03-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 3,336 | 4.00 | 13.3K | 3,336 | — | ↗ |
| 2020-03-30 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 5,000 | 4.06 | 20.3K | 7,630,601 | — | ↗ |
| 2020-03-27 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 4,000 | 4.18 | 16.7K | 7,625,601 | — | ↗ |
| 2020-03-26 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 4.44 | 4.4K | 7,621,601 | — | ↗ |
| 2020-03-24 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 4.40 | 8.8K | 7,620,601 | — | ↗ |
| 2020-03-20 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 4.31 | 8.6K | 7,618,601 | — | ↗ |
| 2020-03-19 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 4,000 | 4.15 | 16.6K | 7,616,601 | — | ↗ |
| 2020-03-17 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 3,440 | 4.00 | 13.8K | 7,612,601 | — | ↗ |
| 2020-03-16 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 600 | 4.15 | 2.5K | 7,609,161 | — | ↗ |
| 2020-03-13 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 3,000 | 4.28 | 12.8K | 7,608,561 | — | ↗ |
| 2020-03-10 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 4,000 | 4.20 | 16.8K | 7,605,561 | — | ↗ |
| 2020-03-09 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 231 | 4.22 | 974.82 | 7,601,561 | — | ↗ |
| 2020-02-25 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 28,400 | 6.68 | 189.7K | 28,400 | — | ↗ |
| 2020-02-25 | Watkins Raymond E. | Officer | A-Award | A | Stock Option (Right to Buy) | 8,000 | 6.07 | 48.6K | 8,000 | — | ↗ |
| 2020-02-25 | Smith Ernest S. | Officer | A-Award | A | Stock Option (Right to Buy) | 8,000 | 6.07 | 48.6K | 8,000 | — | ↗ |
| 2020-02-25 | Royer Scott E. | Officer | A-Award | A | Stock Option (Right to Buy) | 2,000 | 6.07 | 12.1K | 2,000 | — | ↗ |
| 2020-02-25 | Leonard John E. | Officer | A-Award | A | Stock Option (Right to Buy) | 4,000 | 6.07 | 24.3K | 4,000 | — | ↗ |
| 2020-01-23 | Zauderer Maurice | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 98,231 | 5.09 | 500.0K | 1,097,753 | — | ↗ |
| 2020-01-23 | Frieberg Jacob B. | Director | P-Purchase | A | Common Stock | 39,292 | 5.09 | 200.0K | 39,292 | — | ↗ |
| 2020-01-23 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 982,318 | 5.09 | 5.00M | 7,601,330 | — | ↗ |
| 2019-12-31 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 2,737 | 4.85 | 13.3K | 2,737 | — | ↗ |
| 2019-12-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 2,737 | 4.85 | 13.3K | 2,737 | — | ↗ |
| 2019-09-30 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 1,856 | 7.17 | 13.3K | 1,856 | — | ↗ |
| 2019-09-30 | VACCINEX, INC. | Director | A-Award | A | Stock Option (Right to Buy) | 1,856 | 7.17 | 13.3K | 1,856 | — | ↗ |
| 2019-09-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 1,856 | 7.17 | 13.3K | 1,856 | — | ↗ |
| 2019-07-30 | Zauderer Maurice | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 183,824 | 4.08 | 750.0K | 999,522 | — | ↗ |
| 2019-07-30 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 1,838,235 | 4.08 | 7.50M | 6,619,012 | — | ↗ |
| 2019-07-26 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 3.99 | 4.0K | 4,791,521 | — | ↗ |
| 2019-07-25 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 52 | 3.99 | 207.48 | 4,790,521 | — | ↗ |
| 2019-06-30 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 2,385 | 5.52 | 13.2K | 2,385 | — | ↗ |
| 2019-06-30 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 2,385 | 5.52 | 13.2K | 2,385 | — | ↗ |
| 2019-05-15 | Yanni Barbara | Director | A-Award | A | Stock Option (Right to Buy) | 7,718 | 7.78 | 60.0K | 7,718 | — | ↗ |
| 2019-05-15 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 7,718 | 7.78 | 60.0K | 7,718 | — | ↗ |
| 2019-05-15 | MANIAN BALA S | Director | A-Award | A | Stock Option (Right to Buy) | 7,718 | 7.78 | 60.0K | 7,718 | — | ↗ |
| 2019-05-15 | Goater Jeff | Director | A-Award | A | Stock Option (Right to Buy) | 7,718 | 7.78 | 60.0K | 7,718 | — | ↗ |
| 2019-05-15 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 7,718 | 7.78 | 60.0K | 7,718 | — | ↗ |
| 2019-05-15 | Berlin Alejandro M. | Director | A-Award | A | Stock Option (Right to Buy) | 7,718 | 7.78 | 60.0K | 7,718 | — | ↗ |
| 2019-03-31 | Van Strydonck, Gerald E. | Director | A-Award | A | Stock Option (Right to Buy) | 2,501 | 5.26 | 13.2K | 2,501 | — | ↗ |
| 2019-03-31 | Frieberg Jacob B. | Director | A-Award | A | Stock Option (Right to Buy) | 2,501 | 5.26 | 13.2K | 2,501 | — | ↗ |
| 2019-03-15 | Zauderer Maurice | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 20,000 | 4.29 | 85.8K | 20,000 | — | ↗ |
| 2019-03-15 | Watkins Raymond E. | Officer | A-Award | A | Stock Option (Right to Buy) | 8,000 | 3.90 | 31.2K | 8,000 | — | ↗ |
| 2019-03-15 | Smith Ernest S. | Officer | A-Award | A | Stock Option (Right to Buy) | 8,000 | 3.90 | 31.2K | 8,000 | — | ↗ |
| 2019-03-15 | Royer Scott E. | Officer | A-Award | A | Stock Option (Right to Buy) | 2,000 | 3.90 | 7.8K | 2,000 | — | ↗ |
| 2019-03-15 | Leonard John E. | Officer | A-Award | A | Stock Option (Right to Buy) | 4,000 | 3.90 | 15.6K | 4,000 | — | ↗ |
| 2019-03-15 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 3.96 | 4.0K | 4,790,469 | — | ↗ |
| 2019-03-14 | FRIEDBERG ALBERT | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 4.00 | 4.0K | 4,789,469 | — | ↗ |
| 2019-02-07 | Royer Scott E. | Officer | P-Purchase | A | Common Stock | 1,725 | 5.05 | 8.7K | 3,999 | — | ↗ |
| 2019-02-06 | Royer Scott E. | Officer | P-Purchase | A | Common Stock | 275 | 4.57 | 1.3K | 2,274 | — | ↗ |
| 2019-01-15 | Royer Scott E. | Officer | P-Purchase | A | Common Stock | 1,688 | 4.31 | 7.3K | 1,999 | — | ↗ |
| 2018-12-27 | Royer Scott E. | Officer | P-Purchase | A | Common Stock | 311 | 4.15 | 1.3K | 311 | — | ↗ |
| 2018-08-13 | Zauderer Maurice | Director / Officer / 10% Owner | C-Conversion | D | Series D Convertible Preferred Stock | 8,157,067 | 0.00 | — | 0 | — | ↗ |
| 2018-08-13 | Frieberg Jacob B. | Director | J-Other | A | Option (Right to Acquire) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2018-08-13 | FRIEDBERG ALBERT | Director / 10% Owner | C-Conversion | D | Series B1 Convertible Preferred Stock | 2,041,477 | 0.00 | — | 0 | — | ↗ |
| 2018-08-13 | Antibody Investments LLC | 10% Owner | C-Conversion | D | Series C Convertible Preferred Stock | 7,205,882 | 0.00 | — | 0 | — | ↗ |
| 2018-08-09 | Zauderer Maurice | Director / Officer / 10% Owner | — | D | Series B Convertible Preferred Stock | 93,547 | 13.10 | 1.23M | 0 | — | ↗ |
| 2018-08-09 | Yanni Barbara | Director | — | D | Stock option (right to buy) | 6,396 | 13.60 | 87.0K | 0 | — | ↗ |
| 2018-08-09 | Watkins Raymond E. | Officer | — | D | Common Stock | 0 | 0.00 | — | 7,850 | — | ↗ |
| 2018-08-09 | Van Strydonck, Gerald E. | Director | — | D | Stock option (right to buy) | 7,500 | 14.90 | 111.8K | 0 | — | ↗ |
| 2018-08-09 | Smith Ernest S. | Officer | — | D | Common Stock | 0 | 0.00 | — | 16,000 | — | ↗ |
| 2018-08-09 | Royer Scott E. | Officer | — | D | Stock option (right to buy) | 25,000 | 13.60 | 340.0K | 0 | — | ↗ |
| 2018-08-09 | MANIAN BALA S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-09 | Leonard John E. | Officer | — | I | Common Stock | 0 | 0.00 | — | 1,014 | — | ↗ |
| 2018-08-09 | Goater Jeff | Director | — | D | Stock Option (right to buy) | 2,239 | 13.60 | 30.5K | 0 | — | ↗ |
| 2018-08-09 | Frieberg Jacob B. | Director | — | D | Stock option (right to buy) | 6,396 | 13.60 | 87.0K | 0 | — | ↗ |
| 2018-08-09 | FRIEDBERG ALBERT | Director / 10% Owner | — | I | Series A Convertible Preferred Stock | 500,570 | 0.00 | — | 0 | — | ↗ |
| 2018-08-09 | Crane Alan L | Director | — | D | Stock Option (Right to Buy) | 41,000 | 14.90 | 610.9K | 0 | — | ↗ |
| 2018-08-09 | Berlin Alejandro M. | Director | — | D | Stock option (right to buy) | 6,396 | 13.60 | 87.0K | 0 | — | ↗ |
| 2018-08-09 | Antibody Investments LLC | 10% Owner | — | D | Series D Convertible Preferred Stock | 549,444 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-8.1K
Shares Outstanding
2.68M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Maurice Zauderer President and Chief Executive Officer | 411.7K | — | — | 18.6K | — | — | 430.3K | 4.32% | ↗ |
| 2 | 2023 | Ernest S. Smith Senior Vice President, Research and Chief Scientific Officer | 297.3K | — | — | 11.6K | — | — | 308.9K | 3.77% | ↗ |
| 3 | 2023 | Elizabeth E. Evans Senior Vice President, Discovery and Translational Medicine, and Chief Operating Officer | 291.6K | — | — | 11.6K | — | — | 303.2K | 3.84% | ↗ |
| 4 | 2022 | Maurice Zauderer President and Chief Executive Officer | 400.7K | — | — | 24.6K | — | — | 425.3K | 5.79% | ↗ |
| 5 | 2022 | Ernest S. Smith Senior Vice President, Research and Chief Scientific Officer | 284.0K | — | — | 17.6K | — | — | 301.6K | 5.84% | ↗ |
| 6 | 2022 | Elizabeth E. Evans Senior Vice President, Discovery and Translational Medicine, and Chief Operating Officer | 255.5K | — | — | 17.6K | — | — | 273.1K | 6.45% | ↗ |
| 7 | 2021 | Maurice Zauderer President and Chief Executive Officer | 374.9K | — | — | 26.6K | — | — | 401.5K | 6.63% | ↗ |
| 8 | 2021 | Ernest S. Smith Senior Vice President, Research and Chief Scientific Officer | 264.7K | — | — | 19.0K | — | — | 283.8K | 6.70% | ↗ |
| 9 | 2021 | Scott E. Royer Chief Financial Officer | 242.2K | — | — | 11.4K | — | — | 253.6K | 4.50% | ↗ |
| 10 | 2020 | Maurice Zauderer President and Chief Executive Officer | 357.3K | — | — | 87.1K | — | — | 444.3K | 19.60% | ↗ |
| 11 | 2020 | Raymond E. Watkins Former Senior Vice President and Chief Operating Officer | 202.1K | — | — | 33.8K | — | 125.8K | 361.7K | 9.35% | ↗ |
| 12 | 2020 | Ernest S. Smith Senior Vice President, Research and Chief Scientific Officer | 249.7K | — | — | 33.8K | — | — | 283.5K | 11.93% | ↗ |
| 13 | 2020 | Scott E. Royer Chief Financial Officer | 231.7K | — | — | 8.5K | — | — | 240.2K | 3.52% | ↗ |
| 14 | 2019 | Maurice Zauderer President and Chief Executive Officer | 346.9K | — | — | 52.0K | — | — | 398.9K | 13.04% | ↗ |
| 15 | 2019 | Raymond E. Watkins Former Senior Vice President and Chief Operating Officer | 242.4K | — | — | 20.8K | — | — | 263.2K | 7.90% | ↗ |
| 16 | 2019 | Ernest S. Smith Senior Vice President, Research and Chief Scientific Officer | 242.4K | — | — | 20.8K | — | — | 263.2K | 7.90% | ↗ |
| 17 | 2018 | Maurice Zauderer President and Chief Executive Officer | 336.8K | — | — | — | — | — | 336.8K | 0.00% | ↗ |
| 18 | 2018 | Ernest S. Smith Senior Vice President, Research and Chief Scientific Officer | 235.5K | — | — | — | — | — | 235.5K | 0.00% | ↗ |
| 19 | 2018 | Raymond E. Watkins Senior Vice President and Chief Operating Officer | 235.4K | — | — | — | — | — | 235.4K | 0.00% | ↗ |
| 20 | 2017 | Maurice Zauderer President and Chief Executive Officer | 327.7K | 80.4K | — | — | — | — | 408.1K | 0.00% | ↗ |
| 21 | 2017 | Raymond E. Watkins Senior Vice President and Chief Operating Officer | 229.1K | 32.7K | — | — | — | — | 261.7K | 0.00% | ↗ |
| 22 | 2017 | Ernest S. Smith Senior Vice President, Research and Chief Scientific Officer | 229.1K | 32.7K | — | — | — | — | 261.7K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2024-04-02 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Maurice Zauderer | Co-Founder, Chief Executive Officer, President & Director | 437.3K | — |
| Ernest S. Smith | Senior Vice President of Research & Chief Scientific Officer | 339.9K | — |
| Elizabeth E. Evans | Chief Operating Officer and Senior Vice President of Discovery & Translational Medicine | 309.4K | — |
| Jill Sanchez | Chief Financial Officer | 242.2K | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VCNX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
